Your browser doesn't support javascript.
loading
(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma.
Regelink, J C; Raijmakers, P G; Bravenboer, N; Milek, R; Hoetjes, N J; de Kreuk, A M; van Duin, M; Wondergem, M J; Lips, P; Sonneveld, P; Zijlstra, J M; Zweegman, S.
  • Regelink JC; Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands. jc.regelink@meandermc.nl.
  • Raijmakers PG; Department of Internal Medicine, Meander Medical Centre, Amersfoort, The Netherlands. jc.regelink@meandermc.nl.
  • Bravenboer N; Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
  • Milek R; Department of Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands.
  • Hoetjes NJ; Janssen-Cilag B.V., Tilburg, The Netherlands.
  • de Kreuk AM; Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.
  • van Duin M; Department of Internal Medicine, Sint Lucas Andreas Hospital, Amsterdam, The Netherlands.
  • Wondergem MJ; Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Lips P; Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands.
  • Sonneveld P; Endocrine Section, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
  • Zijlstra JM; Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Zweegman S; Department of Haematology, VU University Medical Center, Amsterdam, The Netherlands.
EJNMMI Res ; 6(1): 46, 2016 Dec.
Article en En | MEDLINE | ID: mdl-27246327
ABSTRACT

BACKGROUND:

Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared (18)F-fluoride-PET with the MAR in myeloma patients.

METHODS:

Bone formation was measured before and after bortezomib treatment by determination of the MAR in iliac bone marrow biopsies and the measurement of (18)F-uptake.

RESULTS:

The inter- and intra-individual variations in (18)F-uptake (SUVA50%) were pronounced as 33.50 (range 4.42 to 37.92) and 27.18 (range 4.00 to 31.18), respectively. A significant correlation between the MAR and (18)F-uptake was found (r = 0.80, p = 0.017). There was a heterogeneous response after treatment varying from -2.20 to 4.53.

CONCLUSIONS:

Iliac (18)F-uptake was associated with the local MAR in myeloma patients. Furthermore, (18)F-fluoride-PET demonstrated the heterogeneity of in vivo bone formation, enabling monitoring during treatment.